Premature Ejaculation Clinical Trial
Official title:
Safety and Efficacy of Escitalopram in the Treatment of Premature Ejaculation A Double-Blind, Placebo-Controlled, Fixed-Dose,Randomized Controlled Study
Escitalopram has been claimed to have the highest selectivity for the human serotonin
transporter relative to the noradrenaline or dopamine transporters. This might be associated
with greater clinical efficacy. Most adverse events reported by escitalopram-treated
patients are mild and transient.
In this study, we compare escitalopram with placebo in the treatment of PE.
Safety and Efficacy of Escitalopram in the Treatment of Premature Ejaculation A
Double-Blind, Placebo-Controlled, Fixed-Dose, Randomized controlled Study
Introduction
From an epidemiological perspective, premature ejaculation (PE) has been reported as the
most common male sexual dysfunction with overall prevalence rates estimated at around 30%
.(Laumann et al., 1999).
PE is defined by the Diagnostic and Statistical Manual of Mental Disorders(revision IV)
(DSM-IV-TR) as 'the persistent or recurrent ejaculation with minimal stimulation before, on,
or shortly after penetration and before the person wishes it'. (American Psychiatric
Association, 1994).
ISSM Definition of Premature Ejaculation is a male sexual dysfunction characterized by
ejaculation which always or nearly always occurs prior to or within about one minute of
vaginal penetration; and inability to delay ejaculation on all or nearly all vaginal
penetrations; and negative personal consequences, such as distress, bother, frustration
and/or the avoidance of sexual intimacy (www.issm.info).
Premature ejaculation has been associated with erosion in sexual self-confidence and low
sexual satisfaction in men and their female partners.( Byers & Grenier ; 2003).
Behavioral therapy and psychological counseling are the historically initial approaches in
the treatment of PE.However There is no evidence that non-drug therapy is able to guarantee
long-term cure or improvement of PE. (Rosen, 2004).
These techniques require active involvement of the patients and their partners and the
benefits are generally short-lived, and patients usually relapse. In addition, these
therapies may not be applicable for some cultural and socioeconomic groups. Therefore, some
pharmacological agents have been proposed for the treatment of PE(Rosen, 2004).
The serotoninergic system has an inhibitory effect on the ejaculatory reflex. Selective
serotonin reuptake inhibitors (SSRIs) (paroxetine, fluoxetine, sertraline, citalopram) are
reported to be effective for treating PE (Rosen, 2004; Safarinejad & Hosseini, 2006).
Psychopharmacological studies suggest that PE might be due to decreased serotonergic
neurotransmission through pathways that control ejaculation (Waldinger et al., 1998).
Ejaculation delay induced by SSRIs is due to alterations in specific serotonin receptors in
the central nervous system. The ejaculation-retarding effect of 5-hydroxytryptamine (5-HT,
serotonin) has been attributed to the activation of 5-HT1B and 5-HT2C receptors. By
contrast, stimulation of 5-HT1A receptors has a facilitator effect on ejaculation (Giuliano,
2007). The net effect of acute SSRI administration is only a mild increase of 5-HT
neurotransmission and mild stimulation of the various post-synaptic serotonin receptors
(Waldinger et al., 2005). In contrast, chronic SSRI administration is associated with more
5-HT (serotonin) release into the synapse, stronger increase of 5-HT neurotransmission, and
as a result durable activation of post-synaptic 5-HT receptors (Blier et al., 1988).
Escitalopram has been claimed to have the highest selectivity for the human serotonin
transporter relative to the noradrenaline or dopamine transporters.(Owens et al; 2001) This
might be associated with greater clinical efficacy. Most adverse events reported by
escitalopram-treated patients are mild and transient (Lepola et al; 2003).
In this study, we compare escitalopram with placebo in the treatment of PE.
Objectives:
The objective of the present trial is to assess the safety & efficacy of Escitalopram in the
treatment of premature ejaculation.
Study design:
A Double-Blind, Placebo-Controlled, Fixed-Dose, Randomized Controlled Study.
Setting:
The outpatient clinic of sexual health Kasr El-Einy (Cairo University Hospital), Cairo,
Egypt.
Patients:
One hundred married patients seek medical help for what they consider premature ejaculation
with possible sexual intercourse equal or greater than 1 per week.
Randomization and Allocation Concealment Randomization will be performed using allocation
concealment random assignment schedule for each patient. It will be accomplished using
numbered cards in closed envelopes that assured an equal number of patients in the two
treatment groups.
Exclusion criteria
- Erectile dysfunction accounting to Arabic version of IIEF(International Index of
Erectile Dysfunction)
- Chronic psychiatric or physical illness.
- Alcohol or substance abuse.
- Use of psychotropic and antidepressant medication.
- Patient with prostatitis
- Organic illness causing limitation of SSRI use.
Methods:
Assessment of patient:
1. History taking.
2. General examination.
3. Local genital examination.
4. Self administration of IIEF (Arabic version)
5. Pretreatment IELT(Intravaginal Ejaculatory Latency Time) measured at least 3 times.
Interventions:
Patient undergo a double- blind therapy of Escitalopram (10 mg) orally daily during
breakfast (n=50) or placebo (n=50) for four weeks.
Outcome measure:
Primary outcome: change in geometric mean IELT from baseline to four weeks.
Secondary outcome: changes in the intercourse satisfaction domain values of IIEF(Arabic
version).
Assessment of possible side effects
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02232425 -
IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)
|
Phase 2 | |
Completed |
NCT01439984 -
Trial of PED-1 in Male Patients With Premature Ejaculation
|
Phase 3 | |
Completed |
NCT01184105 -
A Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment of Premature Ejaculation
|
Phase 1 | |
Completed |
NCT01203202 -
Phase 2 Trial of PED-1 and PED-2 in Male Patients With Premature Ejaculation
|
Phase 2 | |
Completed |
NCT03942367 -
Evaluation of the Safety and Effectiveness of the vPatch Device
|
N/A | |
Recruiting |
NCT06425211 -
Effectiveness of Pelvic Floor Therapy for the Management of Erectile Dysfunction and Premature Ejaculation.
|
N/A | |
Completed |
NCT02939495 -
The Efficacy and Safety of Dapoxetine/Sildenafil Combination Therapy
|
Phase 4 | |
Completed |
NCT02572037 -
Research and Clinical Value of New Classification for Premature Ejaculation: Multi-Center Research
|
||
Recruiting |
NCT02581826 -
Safety and Efficacy of Silodosin in the Treatment of Premature Ejaculation
|
Phase 2 | |
Terminated |
NCT00983736 -
Study to Evaluate Efficacy and Safety in Male Subjects With Premature Ejaculation
|
Phase 3 | |
Completed |
NCT00556478 -
Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation
|
Phase 2/Phase 3 | |
Completed |
NCT00549211 -
A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296.
|
Phase 1 | |
Not yet recruiting |
NCT05556083 -
Sildenafil Added Effect in Dapoxetine Non-responding Mono-symptomatic Premature Ejaculation (PE)
|
Phase 2 | |
Completed |
NCT03304808 -
Efficacy of a New Behavioral Treatment for Premature Ejaculation Using a Masturbation Aid Device: Star-Stop 3.0
|
N/A | |
Completed |
NCT00861484 -
Proof of Mechanism in ELT
|
Phase 1 | |
Completed |
NCT02984592 -
Effect of Exercise on Premature Ejaculation
|
N/A | |
Recruiting |
NCT02571101 -
A Phase 2 Study of On-demand Therapy With Clomipramine and Sildenafil Combination in Premature Ejaculation
|
Phase 2 | |
Completed |
NCT03174470 -
Safety Demonstration of Increasing Intensities of Electrical Stimulation Delivered to The Bulbospongiosus Muscle
|
N/A | |
Completed |
NCT02794454 -
A Study to Evaluate Efficacy of Investigational Product HeezOn Ultra -1/ HeezOn Ultra-2 on Male Sexual Health
|
N/A | |
Completed |
NCT02297152 -
A New Treatment for Premature Ejaculation?
|
N/A |